肿瘤细胞治疗研究
英文原题：International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma.
T细胞重定向治疗（TCRT），特别是CAR-T 细胞疗法（CAR T细胞）和双特异性T细胞衔接器（TCEs），代表了多发性骨髓瘤（MM）治疗领域的显著进步。
T细胞重定向治疗（TCRT），特别是CAR-T 细胞疗法（CAR T细胞）和双特异性T细胞衔接器（TCEs），代表了多发性骨髓瘤（MM）治疗领域的显著进步。全球已有数种产品上市，另有数种正在开发中，主要靶向B细胞成熟抗原（BCMA）和G蛋白偶联受体C类第5组成员D（GRPC5D）。多种免疫疗法的相对快速可及性带来了必要性，即需要了解某种药物如何影响后续免疫疗法的安全性和有效性，以便MM医生和患者能够致力于这些疗法的最佳序贯使用。国际骨髓瘤工作组召集了专家小组，审查影响免疫疗法疗效和安全性的患者及疾病相关因素，总结关于序贯治疗的现有信息，并提供一系列核心建议。
T-cell redirecting therapy (TCRT), specifically chimeric antigen receptor T-cell therapy (CAR T-cells) and bispecific T-cell engagers (TCEs) represent a remarkable advance in the treatment of multiple myeloma (MM). There are several products available around the world and several more in development targeting primarily B-cell maturation antigen (BCMA) and G protein-coupled receptor class C group 5 member D (GRPC5D). The relatively rapid availability of multiple immunotherapies brings the necessity to understand how a certain agent may affect the safety and efficacy of a subsequent immunotherapy so MM physicians and patients can aim at optimal sequential use of these therapies. The International Myeloma Working Group conveyed panel of experts to review patient and disease-related factors affecting efficacy and safety of immunotherapy, summarize existing information on sequencing therapy and provide a series of core recommendations.
MEMBER ACCOUNT
登录成功会直接打开下一页。
